Table 2

Discharge therapy and follow-up

VTE specifiedTotalEdmontonRural AlbertaReginaP values
VTE (all combined)p<0.001
 Parenteral anticoagulant alone172 (41.2%)157 (51.6%)6 (20.0%)9 (10.8%)
 Parenteral anticoagulant+warfarin123 (29.5%)52 (17.1)8 (26.7%)63 (75.9%)
 DOAC116 (27.8%)90 (29.6%)16 (53.3%)10 (12.1%)
  Rivaroxaban111 (95.7%)87 (96.7%)15 (93.8%)9 (90.0%)
  Apixaban5 (4.3%)3 (3.3%)1 (6.3%)1 (10.0%)
 Not documented6 (1.4%)5 (1.6%)01 (1.2%)
PE and PE+DVTp=0.55
 Parenteral anticoagulant alone71 (49.3%)64 (48.5%)3 (50.0%)4 (66.7%)
 Parenteral anticoagulant+warfarin20 (13.9%)18 (13.6%)2 (33.3%)0
 DOAC49 (34.0%)46 (34.8%)1 (16.7%)2 (33.3%)
  Rivaroxaban47 (95.9%)44 (95.7%)1 (100.0%)2 (100.0%)
  Apixaban2 (4.1%)2 (4.3%)00
 Not documented4 (2.8%)4 (3.0%)00
DVT alonep<0.001
 Parenteral anticoagulant alone101 (36.9%)93 (54.1%)3 (12.5%)5 (6.5%)
 Parenteral anticoagulant+warfarin103 (37.7%)34 (19.8%)6 (25.0%)63 (81.8%)
 DOAC67 (24.5%)44 (25.6%)15 (62.5%)8 (10.4%)
  Rivaroxaban64 (95.5%)43 (97.7%)14 (93.3%)7 (87.7%)
  Apixaban3 (5.4%)1 (2.3%)1 (6.7%)1 (12.5%)
 Not documented2 (0.7%)1 (0.1%)01 (1.3%)
Follow-up*
 Family doctor124 (26.8%)61 (20.1%)16 (53.3%)47 (56.6%)
 Return to ED16 (3.4%)5 (1.6%)7 (23.3%)4 (4.8%)
 Specialist25 (5.4%)13 (4.3%)1 (3.3%)11 (13.3%)
 VTE clinic186 (40.2%)180 (59.2%)00
 Anticoagulation clinic19 (4.1%)3 (1.0%)1 (3.3%)15 (18.1%)
 Other55 (11.9%)44 (14.5%)1 (3.3%)10 (12.0%)
 Not documented37 (8.0%)23 (7.6%)5 (16.7%)9 (10.8%)
  • *Not mutually exclusive.

  • DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; ED, emergency department; PE, pulmonary embolism; VTE, venous thromboembolism.